CHK1 INHIBITION RESTORES INOTUZUMAB OZOGAMICIN CITOTOXICITY ON CD22-POSITIVE CELLS EXPRESSING MUTANT P53

被引：0
|
作者：
Tirro, E. [1 ,2 ]
Massimino, M. [1 ,2 ]
Manzella, L. [1 ,2 ]
Parrinello, N. L. [3 ]
Stagno, F. [3 ]
Palumbo, G. A. [3 ]
Romano, A. [3 ]
Di Raimondo, F. [3 ]
Vigneri, P. [1 ,2 ]
机构：
[1] Univ Catania, Dept Clin & Expt Med, Catania, Italy
[2] AOU Policlin Vittorio Emanuele, Ctr Expt Oncol & Hematol, Catania, Italy
[3] Univ Catania, Div Hematol, AOU Policlin Vittorio Emanuele, Catania, Italy
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO073
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
    Tirro, Elena
    Massimino, Michele
    Romano, Chiara
    Pennisi, Maria Stella
    Stella, Stefania
    Vitale, Silvia Rita
    Fidilio, Annamaria
    Manzella, Livia
    Parrinello, Nunziatina Laura
    Stagno, Fabio
    Palumbos, Giuseppe Alberto
    La Cava, Piera
    Romano, Alessandra
    Di Raimondo, Francesco
    Vigneri, Paolo G.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [2] CHK1/2 INHIBITION RESTORES THE ANTIPROLIFERATIVE EFFECT OF THE IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) ON CD22-POSITIVE CELLS EXPRESSING MUTANT P53
    Massimino, M.
    Tirro, E.
    Fidilio, A.
    Chiarenza, A.
    Palumbo, G.
    Romano, A.
    Manzella, L.
    Di Raimondo, F.
    Stagno, F.
    Vigneri, P.
    HAEMATOLOGICA, 2016, 101 : S88 - S89
  • [3] CHK1 inhibition enhances chemosensitivity of p53 deficient osteosarcoma cells
    Xu, Gufeng
    Wang, Hongmei
    Rainusso, Nino C.
    Flores, Ricardo J.
    Triche, Timothy
    Man, Tsz-Kwong
    Lau, Ching C.
    CANCER RESEARCH, 2011, 71
  • [4] Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1
    Vance, Sean M.
    Liu, Erqi
    Zhao, Lili
    Parsels, Joshua D.
    Parsels, Leslie A.
    Brown, Jeffrey L.
    Maybaum, Jonathan
    Lawrence, Theodore S.
    Morgan, Meredith A.
    CELL CYCLE, 2011, 10 (24) : 4321 - 4329
  • [5] Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
    DeAngelo, Daniel J.
    Stock, Wendy
    Stein, Anthony S.
    Shustov, Andrei
    Liedtke, Michaela
    Schiffer, Charles A.
    Vandendries, Erik
    Liau, Katherine
    Ananthakrishnan, Revathi
    Boni, Joseph
    Laird, A. Douglas
    Fostvedt, Luke
    Kantarjian, Hagop M.
    Advani, Anjali S.
    BLOOD ADVANCES, 2017, 1 (15) : 1167 - 1180
  • [6] Correlation of gemcitabine sensitization by Chk1 inhibition with p53 status
    Pan, Shanlong
    Li, Rongrong
    Tao, Li
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (03) : 270 - 274
  • [7] TARGETING CHK1 AND AKT CROSSTALK IN MUTANT P53 PEDIATRIC GLIOBLASTOMA
    Stamatkin, Chris
    Dave, Nimita
    Shannon, Harlan
    Bailey, Barbara
    Ding, Jixin
    Saadatzadeh, Reza
    Murray, Mary
    Cohen-Gadol, Aaron
    Renbarger, Jamie
    Pollok, Karen
    NEURO-ONCOLOGY, 2017, 19 : 54 - 54
  • [8] Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells
    Vitale, Ilio
    Senovilla, Laura
    Galluzzi, Lorenzo
    Criollo, Alfredo
    Vivet, Sonia
    Castedo, Maria
    Kroemer, Guido
    CELL CYCLE, 2008, 7 (13) : 1956 - 1961
  • [9] Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents - Differential activity in cells expressing or not p53
    Carrassa, L
    Broggini, M
    Erba, E
    Damia, G
    CELL CYCLE, 2004, 3 (09) : 1177 - 1181
  • [10] The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo
    Ma, Zhikun
    Ya, Guoliang
    Zhou, Bo
    Fan, Yonggang
    Gao, Shegan
    Feng, Xiaoshan
    MOLECULAR MEDICINE REPORTS, 2012, 6 (04) : 897 - 903
12345